Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
63,641.11 +130.77 (+0.21%) CMC Crypto 200
1,369.76 +57.14 (+4.36%)
Eli Lilly and Company (LLYC.VI)
| Previous close | 702.90 |
| Open | 696.90 |
| Bid | 550.00 x N/A |
| Ask | 686.60 x N/A |
| Day's range | 684.70 - 699.50 |
| 52-week range | 339.00 - 736.00 |
| Volume | |
| Avg. volume | 11 |
| Market cap | 650.99B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 124.95 |
| EPS (TTM) | 5.48 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | 4.75 (0.68%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
- Yahoo Finance Video
Weight loss drugs and the many use cases in medical treatments
Novo Nordisk's (NVO) Ozempic and Wegouvy and Eli Lilly's (LLY) Zepbound are the leading names in the latest GLP-1 weight loss drug cycle, a trend that has seen a variety of use cases sprout up since these brand names' inceptions late last year. Yahoo Finance Health Reporter Anjalee Khemlani explains the new use cases being found for this class of drugs, including infertility treatments and even benefits for Alzheimer's patients. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Luke Carberry Mogan.
FX EmpireEli Lilly Shares Show Healthy Rise
Eli Lilly and Company (LLY) shares are up in 2024 to the tune of 28% so far. Looking under the surface, it’s clear to see why this biopharmaceuticals stock is so powerful.
ZacksPharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
